Genentech’s (JOBS) Psoriasis Drug Raptiva Gets FDA Warning

October 17, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, Oct 16 (Reuters) - U.S. health regulators have ordered strong black-box warnings for Genentech Inc's psoriasis drug, Raptiva, saying patients given the once-weekly injections are at risk for life-threatening infections.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals

Genentech, Inc. Food and Drug Administration (FDA)